In a filing, Tonix Pharmaceuticals Holding Corp revealed its Chief Executive Officer LEDERMAN SETH acquired Company’s shares for reported $86200.0 on May 15 ’25. In the deal valued at $21.55 per share,4,000 shares were bought. As a result of this transaction, LEDERMAN SETH now holds 4,005 shares worth roughly $0.17 million.
Noble Capital Markets initiated its Tonix Pharmaceuticals Holding Corp [TNXP] rating to an Outperform in a research note published recently. A number of analysts have revised their coverage, including ROTH Capital’s analysts, who increased its forecast for the stock in mid April from “a Neutral” to “a Buy”. ROTH Capital also remained covering TNXP and has increased its forecast on August 18, 2017 with a “Buy” recommendation from previously “Neutral” rating. ROTH Capital revised its rating on September 07, 2016. It rated TNXP as “a Neutral” which previously was an “a Buy”.
Price Performance Review of TNXP
On Friday, Tonix Pharmaceuticals Holding Corp [NASDAQ:TNXP] saw its stock jump 2.87% to $41.81. Over the last five days, the stock has gained 9.87%. Tonix Pharmaceuticals Holding Corp shares have risen nearly 26.79% since the year began. Nevertheless, the stocks have fallen -91.36% over the past one year. While a 52-week high of $363.20 was reached on 01/28/25, a 52-week low of $6.76 was recorded on 03/04/25. SMA at 50 days reached $23.51, while 200 days put it at $21.19.
Levels Of Support And Resistance For TNXP Stock
The 24-hour chart illustrates a support level at 38.55, which if violated will result in even more drops to 36.45. On the upside, there is a resistance level at 42.26. A further resistance level may holdings at 43.86. The Relative Strength Index (RSI) on the 14-day chart is 71.35, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 3.93, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 13.86%. Stochastics %K at 78.87% indicates the stock is a holding.
The most recent change occurred on February 17, 2016 when Oppenheimer resumed its ‘”an Outperform”‘ rating for the stock and retained the price target to $10.
